Beta Drugs Limited — Investor Meet, 22-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Beta Drugs' FY26 net revenue grew to INR396 Cr, with EBITDA at INR86.85 Cr and margins at 22.57%. Net profit margin was 10.78%, impacted by extraordinary expenses. Branded sales rose 20%, Derma 35%, and API 23%. Exports declined 11% due to delayed tenders but management projects over 50% growth in FY27. The company acquired 66.1% in Nivian (IVF) for INR69.4 Cr, aiming for 30% growth. Management targets doubling sales to INR850-900 Cr by FY30, driven by new products and regulated market expansion. Sentiment is confident about achieving diversified growth.